Scoping Review of Pharmacological Agents for Preventing Decompensation in Compensated Liver Cirrhosis Excluding Beta-Blockers
<h2>Cover Page</h2>
<p>Scoping Review of Pharmacological Agents for Preventing Decompensation in Compensated Liver Cirrhosis Excluding Beta-Blockers</p>
<p>Student Name</p>
<p>Professor</p>
<p>Course</p>
<p>Institution</p>
<p>Date</p>
<h2>List of Abbreviations</h2>
<h2>Overview of Pharmacological Agents for Preventing Decompensation in Compensated Liver Cirrhosis</h2>
<h2>Systematic Identification and Selection of Eligible Studies</h2>
<h3>PRISMA Flow Diagram for Study Selection</h3>
<h3>Summary of Included Pharmacological Intervention Studies</h3>
<h3>Reported Clinical Outcomes Across Pharmacological Classes</h3>
<h3>Risk of Bias Assessment of Included Studies</h3>
<h2>Critical Evaluation of Pharmacological Strategies for Preventing Hepatic Decompensation</h2>
<h3>Statins as Vascular Modulators in Cirrhosis Management</h3>
<h3>Rifaximin and Modulation of the Gut–Liver Axis</h3>
<h3>Systemic Immunomodulatory Effects of Long-Term Rifaximin Therapy</h3>
<h3>Anticoagulants for Preventing Portal Vein Thrombosis and Fibrosis Progression</h3>
<h2>Critical Appraisal of the Current Evidence Base</h2>
<h3>Methodological Strengths of Existing Research</h3>
<h3>Limitations and Sources of Evidence Heterogeneity</h3>
<h2>Research Gaps and Priorities for Future Investigation</h2>
<h3>Need for Long-Term Randomized Controlled Trials</h3>
<h3>Underrepresentation of Emerging Pharmacological Agents</h3>
<h3>Need for Combination Therapy and Precision Medicine Research</h3>
<h2>Clinical Implications for Prevention of Cirrhosis Decompensation</h2>
<h3>Translation of Evidence into Clinical Practice</h3>
<h3>Individualized Pharmacological Decision-Making</h3>
<h3>Safety Monitoring and Pharmacovigilance Considerations</h3>
<h2>Integrated Synthesis of Evidence and Future Directions</h2>
<h2>References</h2>